Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product R&D

Brake for gas

China newco Elpiscience links 4-1BB boost to PD-L1 block in first of 12 programs

Karen Tkach Tuzman, Associate Editor
April 26, 2018 11:41 PM UTC

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage leading immunotherapies by widening the gap between efficacy and toxicity.

Backed by Lilly Asia Ventures and headed by venture partner and former Roche BD&L executive Darren Ji, the newco is the latest example of the momentum in China for harnessing innovative science to compete both locally and globally. Ji, who co-founded the company as CEO in 2017, unveiled the company’s lead compound and pipeline strategy at the China Healthcare Investment Conference (CHIC) meeting last month in Shanghai. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alligator Bioscience AB

American Association for Cancer Research

Aptevo Therapeutics Inc.

Astrazeneca plc

Bristol Myers Squibb Co.

Elpiscience Biopharmaceuticals Inc.

Enumeral Biomedical Holdings Inc.